Itacitinib has indeed been assessed in phase I and II studies on reducing CAR-T induced cytokine shock syndrome CRS,40,41 which is associated with elevated levels of TNFα and IFNγ.2 The gene discussed is IFNG; the disease is congenital rubella syndrome.